Literature DB >> 16098311

Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Michael H Davidson1, Kevin C Maki, Thomas A Pearson, Richard C Pasternak, Prakash C Deedwania, James M McKenney, Gregg C Fonarow, David J Maron, Benjamin J Ansell, Luther T Clark, Christie M Ballantyne.   

Abstract

The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098311     DOI: 10.1016/j.amjcard.2005.04.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  65 in total

1.  Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).

Authors:  Shaun G Goodman; Anatoly Langer; Natacha R Bastien; Ruth McPherson; Gordon A Francis; Jacques J Genest; Lawrence A Leiter
Journal:  Can J Cardiol       Date:  2010-11       Impact factor: 5.223

2.  Organizing services for cardiovascular prevention.

Authors:  Robert C Block; Thomas A Pearson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 3.  Novel nonstatin strategies to lower low-density lipoprotein cholesterol.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

4.  Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.

Authors:  Salim S Virani
Journal:  Tex Heart Inst J       Date:  2011

5.  Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II.

Authors:  Luther T Clark; Kevin C Maki; Ron Galant; David J Maron; Thomas A Pearson; Michael H Davidson
Journal:  J Gen Intern Med       Date:  2006-04       Impact factor: 5.128

6.  SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.

Authors:  Josephine H Li; Sunil Suchindran; Svati H Shah; William E Kraus; Geoffrey S Ginsburg; Deepak Voora
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

7.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Authors:  Kevin Fitzgerald; Maria Frank-Kamenetsky; Svetlana Shulga-Morskaya; Abigail Liebow; Brian R Bettencourt; Jessica E Sutherland; Renta M Hutabarat; Valerie A Clausen; Verena Karsten; Jeffrey Cehelsky; Saraswathy V Nochur; Victor Kotelianski; Jay Horton; Timothy Mant; Joseph Chiesa; James Ritter; Malathy Munisamy; Akshay K Vaishnaw; Jared A Gollob; Amy Simon
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

8.  ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.

Authors:  C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

9.  [Durability of the effects of a quality improvement intervention in hypertensive patients on long-term follow-up (CICLO-RISK study)].

Authors:  Manuel Angel Gómez Marcos; Emiliano Rodríguez Sánchez; Emilio Ramos Delgado; Carmen Fernández Alonso; Angel Luis Montejo Gónzalez; Luis García Ortiz
Journal:  Aten Primaria       Date:  2009-05-15       Impact factor: 1.137

Review 10.  Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.

Authors:  Yasushi Saito
Journal:  Vasc Health Risk Manag       Date:  2009-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.